Observation of Glomerular Filtration Change in Chronic Hepatitis B Patients Using Tenofovir Disoproxil Fumarate

Abstract

INTRODUCTION: This study was conducted to assess kidney function tests in outpatient individuals with a diagnosis of chronic hepatitis B who were receiving treatment with Tenofovir Disoproxil Fumarate (TDF). METHODS: Our study included patients who presented to the Infectious Diseases Polyclinic at XXX Hospital with a diagnosis of chronic hepatitis B (CHB) and were treated with Tenofovir Disoproxil Fumarate (TDF). The hospital data, available retrospectively since 2013, allowed us to examine patient follow-ups up to that year. As a result, we were able to analyze a maximum follow-up period of nine years. The study encompassed individuals over 18 years of age whose data were complete and who were regularly monitored in the outpatient clinic. RESULTS: Among the subjects, 69% (n: 69) were male, and 31% (n: 31) were female. Significant reductions in glomerular filtration rates (GFR) were observed in the 4th and 6th years compared to GFR measurements before initiating TDF treatment (p<0.05). Furthermore, creatinine values at the 4th and 6th years were significantly lower compared to the pre-treatment values (p<0.05). No modifications were made to the patients' treatment during the follow-up period. DISCUSSION AND CONCLUSION: Our findings reveal differences in GFR and creatinine values similar to those observed in most studies involving patients using TDF. It is evident that TDF can lead to renal impairment. Thus, it is essential to closely monitor patients and make necessary treatment adjustments when indicated. In cases of renal insufficiency, alternative treatment options should be considered at the initiation of therapy. This approach can contribute to the prevention of nephrotoxicity.

Keywords

• chronic hepatitis b
• tenofovir disoproxil fumarate
• nephrotoxicity